BQ Prime's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer BQ Prime's subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Prabhudas Lilladher Report
Eris Lifesciences Ltd.'s Q1 FY24 reported healthy Ebitda of Rs 1.7 billion (up 31.4% YoY) with sharp improvement in operating profit margin at 36.4% (up 400 basis points YoY).
We expect margins to sustain as revenue scales up from recent acquisitions which is currently operating at sub optimal profitability.
Eris Lifesciences has multiple growth levers such as broad based offerings in derma segment, opportunities in cardio metabolic market with patent expirations and benefits of operating leverage, as revenue scales up from these acquisitions.
We maintain our ‘Buy' rating with revised target price of Rs 910, valuing 16 times enterprise value/Ebitda on FY25E.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.